Susan Galbraith: Each person’s treatment needs to be personal
Susan Galbraith, Executive Vice President in Oncology R&D at AstraZeneca, shared a post on LinkedIn:
“Each person’s cancer diagnosis is personal and that’s why treatment needs to be too.
At AstraZeneca, our Oncology R and D strategy is grounded in a precision medicine approach that leverages transformational technologies to help diagnose and treat tumors across all stages of disease. Computational pathology is an active area of research that uses these technologies to predict which patients may have the best chance to benefit from a specific treatment. We envision a future where computational pathology becomes standard practice so more patients may experience improved outcomes.
Learn more about how computational pathology is redefining cancer care.”
Video attached to the post.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023